Bradford A. Zakes

President & Chief Executive Officer

Mr. Zakes has served as Cerevast’s President and Chief Executive Officer since its inception in September 2009. Previously, he served as President and CEO of ImaRx Therapeutics, Inc. a publicly traded biopharmaceutical company focused on the development of microsphere technology and biotherapeutics. Mr. Zakes has spent 25+ years in various segments of the pharmaceutical, biotechnology and med-tech industries. Following his career as a commissioned officer in the United States Army, Mr. Zakes held positions at Hazleton Laboratories, Glaxo (currently Glaxo Smithkline) and ICOS Corporation. While at Glaxo, Mr. Zakes played an active role in the clinical development of Zantac™ and managed the sNDA clinical program that led to the approval of Serevent™ for chronic obstructive pulmonary disease. Mr. Zakes holds a BS degree in Biology from Oregon State University, an MS degree in Toxicology from the American University and an MBA from Duke University’s Fuqua School of Business. Additionally, Mr. Zakes serves on the Board of Directors for the Biotechnology Industry Organization (BIO) as well as the Emerging Company Section Governing Body and the Standing Committees on International Affairs and Budget and Audit for BIO.

W.J. Tyler, Ph.D.

Chief Scientific Officer

Dr. Tyler is an Associate Professor in the School of Biological and Health Systems Engineering at Arizona State University. Dr. Tyler utilizes cutting-edge technology to investigate a wide range of problems in modern neuroscience with active research approaches spanning single ion channel biophysics to fMRI and EEG in behaving humans. He has made leading contributions to our understanding of synaptic transmission and brain plasticity underlying sensory encoding and cognitive processes, such as learning and memory. He has also led the scientific development and commercialization of non-invasive neuromodulation technologies. He was a co-founder and the Chief Scientific Officer of Thync, Inc. He has received several awards including a prestigious McKnight Endowment Fund for Neuroscience Technological Innovation Award and a Defense Advanced Projects Research Agency (DARPA) Young Faculty Award for his leadership and pioneering of neurotechnology. He is the author or co-author on 25+ peer-reviewed publications in leading scientific journals, as well as an inventor or co-inventor on more than 25 patents on methods and devices for non-invasive neuromodulation, brain stimulation, communications and cognitive enhancement. Dr. Tyler received his B.S. and Ph.D. from the University of Alabama at Birmingham and conducted his postdoctoral fellowship at Harvard University.

Mark Moehring, Ph.D.

Chief Technology Officer

Dr. Moehring is a recognized leader in the field of ultrasound with 30+ years of experience in medical ultrasound instrument design and signal processing. His research and product development focus has been in the field of Doppler ultrasound with primary emphasis in diagnostic and therapeutic cranial applications.   Dr. Moehring has been central to technology development in areas as diverse as transcranial blood flow monitoring, otitis media detection in children, embolus detection, and ultrasound enhanced thrombolysis.  Dr. Moehring is a senior member of the Institute of Electrical and Electronics Engineers (IEEE) and holds a Bachelor of Science in Physics from Harvey Mudd College and a Master of Science and Ph.D. in Electrical Engineering from the University of Washington.  Dr. Moehring is the inventor of 16 issued patents in ultrasound and hemodynamic monitoring technology.

Andrew Leo

Vice President of Quality and Regulatory Affairs

Mr. Leo is Quality and Regulatory Affairs professional with 25+ years of experience in biomedical research and development organizations, including Brigham and Women’s Hospital. He was formerly the Sr. Director of Quality and Laboratory Operations at Sonus Pharmaceuticals.  He has established and maintained quality management systems to support biomedical development programs for several organizations, including Cerevast.  As company’s management representative, he had successfully help Cerevast obtain ISO 13485:2016 and CE Marking certifications.   Mr. Leo received a BS degree in Chemistry from the University of Washington and an MBA from the University of Phoenix.